Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,209.14 +36.99 (+0.45%) Bitcoin USD
59,166.59 +810.18 (+1.39%) CMC Crypto 200
1,277.18 +0.20 (+0.02%)
AMGN Jan 2026 195.000 call
| Previous close | 86.60 |
| Open | 86.60 |
| Bid | 0.00 |
| Ask | 0.00 |
| Strike | 195.00 |
| Expiry date | 2026-01-16 |
| Day's range | 86.60 - 86.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 21 |
- Yahoo Finance Video
Amgen, DraftKings, Live Nation: Trending tickers
Shares of Amgen (AMGN) are soaring at Thursday's market close after reporting first quarter results, with revenue exceeding expectations. The biotechnology giant's revenue rose by 22% during the quarter. DraftKings (DKNG) also delivered a strong earnings report, surpassing analysts' estimates on both the top and bottom lines. Buoyed by this performance, the company raised its full-year outlook. Live Nation (LYV) topped revenue estimates in its first quarter earnings, although the company reported a loss of $0.53 per share. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Angel Smith
- Reuters
US STOCKS-Futures rise on Apple, Amgen boost; jobs data awaited
Futures tied to Wall Street's main indexes gained on Friday, lifted by upbeat corporate updates from Apple and Amgen, while traders braced for a key jobs report for a clearer outlook on the labor market and the interest rate path. Apple jumped 6.1%, outpacing other megacap stocks in premarket trading after the iPhone maker unveiled a record $110 billion share buyback program and beat modest expectations for quarterly results and forecast.
ReutersNovo Nordisk drops 5% after rival Amgen teases weight-loss drug data
Novo Nordisk were last down 4.4% by 1022 GMT, having hit their lowest in two months earlier in the day. Amgen on Thursday said it was very encouraged after completing an interim analysis of its mid-stage study of experimental weight-loss drug MariTide, which, if approved, would compete Novo's Wegovy and Eli Lilly's Zepbound. "Novo's share price today is certainly factoring in some negative reaction to Amgen's positive commentary on MariTide development yesterday," Kepler Cheuvreux analyst David Evans said, but added that "a continued negative reaction to results and pricing concerns yesterday is likely also a smaller part of the move today".
